Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Yeager, C. Nguyen, K. Colvin, D. Ivy, K. Stenmark (Aurora, United States Of America). Evidence of lymphangiogenesis in pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 1085

Member's Comments

No comment yet.

Related content which might interest you: Angiogenesis and coagulation in the development of pulmonary hypertension in sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 608s Year: 2007 Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2015; 46: 431-443 Year: 2015 Endothelial NO and its pathophysiologic regulation Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease Year: 2007 First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017 Year: 2018 Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature Source: Eur Respir J 2014; 44: 1275-1288 Year: 2014 The Role of Inflammation in promoting pulmonary hypertension in idiopatchi and connective tissue disease-associated PAH Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Updates in pulmonary hypertension and other pulmonary vascular diseases Source: Breathe, 15 (3) 241; 10.1183/20734735.0187-2019 Year: 2019 CFTR involvement in the pathogenesis of pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Chronic thromboembolic pulmonary hypertension: role of medical therapy Source: Eur Respir J 2013; 41: 985-990 Year: 2013 Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (2) 2101645; 10.1183/13993003.01645-2021 Year: 2021 The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations Source: Eur Respir Rev 2014; 23: 350-355 Year: 2014 Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 LATE-BREAKING ABSTRACT: Evidence for a critical contribution of pericytes in pulmonary arterial hypertension pathogenesis Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 When is pulmonary hypertension not pulmonary hypertension? Source: Eur Respir J 2001; 18: Suppl. 33, 522s Year: 2001 Macitentan reduces progression of TGF-ß1-induced pulmonary fibrosis and pulmonary hypertension Source: Eur Respir J, 52 (2) 1701857; 10.1183/13993003.01857-2017 Year: 2018 Angiogenesis in chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2012 - Pulmonary circulation: acute and chronic pulmonary embolism Year: 2012 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Molecular determinants of cardiac and pulmonary vascular remodeling in scleroderma-related pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension in connective tissue diseases Year: 2008 Pulmonary hypertension in sickle cell disease Source: Annual Congress 2007 - ACCP1 - Pulmonary hypertension in sickle cell disease Year: 2007